The COVID-19 pandemic is caused by SARS-CoV-2, a novel strain of coronavirus. Patients with SARS-CoV-2 infection experience a range of clinical manifestations including respiratory distress, cytokine storm, cardiovascular complications and organ dysfunction. Currently, there is no proven treatment for COVID-19. The medical treatment provided includes anti-viral agents, supportive care and repurposed drugs. BioVision offers a broad range of Biochemicals for Scientists to rapidly develop drugs to fight COVID-19. BioVision’s products have been well validated by researchers all around the world, with an increasing number of citations available in scientific publications.

Many anti-viral agents such as Remdesivir, Favipiravir, Ribavirin, Atazanavir and protease inhibitors such as Lopinavir and Ritonavir are in clinical trials for COVID-19. Remdesivir (initially named GS-5734) is an adenosine analogue that has a broad-spectrum of antiviral activity. In cells, it is activated to the nucleoside triphosphate form, which then acts as an analogue of ATP and competes with the natural ATP substrate. It incorporates into the growing viral RNA and stops viral replication. Remdesivir is recommended for treating patients with severe COVID-19 by the NIH COVID-19 Treatment Guidelines Panel. Due to an immediate need for the treatment of SARS-CoV-2, many approved drugs are being repurposed for clinical management. Anti-inflammatory drugs such as Baricitinib, an inhibitor of Janus kinase (JAK1 and JAK2) could be beneficial in treating COVID-19 when used in combination with anti-viral drugs. Baricitinib may reduce the endocytosis of the virus into the target cells and can also act on the inflammation cascade. Dexamethasone, an anti-inflammatory glucocorticoid, is recommended for treating patients with COVID-19 who are ventilated or require supplemental oxygen.

Anti-parasitic agents such as Ivermectin and Nitazoxanide inhibit SARS-CoV-2 in vitro. These drugs are being evaluated in patients for use in combination therapy. Proteomics and viral screens have shown that drugs targeting human proteins, which interact with SARS-CoV-2 proteins, display anti-viral activity. These potential drugs include Pridopidine, Ditolylguanidine, RIPA-56, which are modulators of sigma1, sigma2 receptors and RIP1 kinase that interact with SARS-CoV-2 proteins Nsp6, Orf9C and Nsp12. Other commonly prescribed drugs such as Famotidine and Omeprazole that are used to treat gastroesophageal reflux disease and peptic ulcer have also shown protective effects and are in clinical trials for COVID-19.


Features & Benefits

Highly Pure and Selective
Cell permeable
Broad Range of Inhibitors to choose from
Bulk Quotes Available